Evidence map›Paper›PMID 41279497›Full record

ArticlebioRxiv : the preprint server for biology2025

Epstein-Barr Virus Encoded lncRNAs Control the Viral Lytic Switch.

Zhixuan Li, Yifei Liao, Weiyue Ding, Davide Maestri, Scott L Grote, Gabriel A Romero Agosto, Laura A Murray-Nerger, Rui Guo, Bo Zhao, Silvi Rouskin and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhixuan LiDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Yifei LiaoDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-0081-9548
Weiyue DingDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Davide MaestriDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Scott L GroteDepartment of Microbiology, Harvard Medical School, Boston, MA 02115.
Gabriel A Romero AgostoDepartment of Microbiology, Harvard Medical School, Boston, MA 02115.
Laura A Murray-NergerDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Rui GuoDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Bo ZhaoDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Silvi RouskinDepartment of Microbiology, Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-2042-6642
Mingxiang TengDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.ORCID 0000-0002-8536-8941
Benjamin E GewurzDivision of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

Funding

Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Italo Tempera · 2023 to 2026
$12.0M
B cell determinants of EBV latency (supplement)U01CA275301 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, Benjamin Elison Gewurz · 2022 to 2026
$4.0M
Epstein-Barr virus LMP1 mediated oncogenicityR01CA228700 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2019 to 2026
$3.3M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
NCI NIH HHS P01 CA269043NCI NIH HHS R01 CA228700NCI NIH HHS U01 CA275301NIAID NIH HHS R01 AI164709
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) uses a biphasic lifecycle, switching between latent and lytic phases to persistently infect most adults. Latency is observed in most tumor cells of the 200,000 EBV-associated cancers/year. EBV reactivation is increasingly implicated in autoimmune diseases, including multiple sclerosis. However, mechanisms that regulate EBV reactivation have remained incompletely understood. Here, we leveraged multi-omic approaches to reveal the existence of pro-latency and a pro-lytic viral long noncoding RNAs (lncRNAs) that counter-regulate the lytic switch. Known reactivation triggers rapidly induced expression of the pro-lytic lncRNA, which encodes an RNA G-quadruplex that mediated its interaction with CTCF. The pro-lytic lncRNA occupies viral origin of lytic replication enhancers and promotes their looping to the immediate early lytic promoter to trigger reactivation. The pro-latency lncRNA duplexes with the pro-lytic RNA to impede its interactions with CTCF. These studies lay a foundation for therapeutic approaches to manipulate the EBV lytic switch.

Indexed as

cohesinCTCFDNA loopingenhancerepigeneticgamma-herpesvirushistone demethylasehistone methyltransferaselatencylymphomalytic induction therapylytic reactivationpromoter

Identifiers

PMID41279497
PMCPMC12636365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.